Overview

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Status:
Completed

Trial end date:
2016-04-28

Target enrollment:

Participant gender:

Summary

The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

Solifenacin Succinate